Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
Doxorubicin has been an integral part of the treatment of women with breast cancer for many
years. Since amrubicin may have more activity than doxorubicin, as well as less
cardiotoxicity, evaluation of amrubicin in the treatment of advanced breast cancer should be
a priority. In this Phase II study, the investigators propose an evaluation of single-agent
amrubicin as second- or third-line treatment for women with metastatic breast cancer.